|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.310 USD | -2.96% |
|
-1.50% | -28.02% |
| 07-22 | Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 | CI |
| 07-22 | Alzamend Neuro, Inc. Auditor Raises 'Going Concern' Doubt | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALZAMEND NEURO, INC. | Other Biotechnology & Medical Research | -2.96% | -1.50% | -28.02% | -41.78% | -99.98% | 6.28M |  | |  |
- Stock Market
- Stocks
- ALZN Stock
- Charts Alzamend Neuro, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
